DYN vs. TGTX, RCKT, VERA, ARVN, KROS, RNA, AMPH, CORT, GERN, and NAMS
Should you be buying Dyne Therapeutics stock or one of its competitors? The main competitors of Dyne Therapeutics include TG Therapeutics (TGTX), Rocket Pharmaceuticals (RCKT), Vera Therapeutics (VERA), Arvinas (ARVN), Keros Therapeutics (KROS), Avidity Biosciences (RNA), Amphastar Pharmaceuticals (AMPH), Corcept Therapeutics (CORT), Geron (GERN), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical preparations" industry.
TG Therapeutics (NASDAQ:TGTX) and Dyne Therapeutics (NASDAQ:DYN) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, community ranking and risk.
TG Therapeutics has a net margin of 14.24% compared to TG Therapeutics' net margin of 0.00%. Dyne Therapeutics' return on equity of 33.79% beat TG Therapeutics' return on equity.
TG Therapeutics has a beta of 2.33, suggesting that its stock price is 133% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.
TG Therapeutics received 638 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. Likewise, 76.77% of users gave TG Therapeutics an outperform vote while only 68.42% of users gave Dyne Therapeutics an outperform vote.
TG Therapeutics has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, TG Therapeutics had 22 more articles in the media than Dyne Therapeutics. MarketBeat recorded 36 mentions for TG Therapeutics and 14 mentions for Dyne Therapeutics. TG Therapeutics' average media sentiment score of 0.42 beat Dyne Therapeutics' score of 0.16 indicating that Dyne Therapeutics is being referred to more favorably in the news media.
58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 9.2% of TG Therapeutics shares are held by insiders. Comparatively, 20.8% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
TG Therapeutics presently has a consensus price target of $29.83, suggesting a potential upside of 84.27%. Dyne Therapeutics has a consensus price target of $37.75, suggesting a potential upside of 44.75%. Given Dyne Therapeutics' higher possible upside, research analysts plainly believe TG Therapeutics is more favorable than Dyne Therapeutics.
Summary
TG Therapeutics beats Dyne Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Dyne Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dyne Therapeutics Competitors List
Related Companies and Tools
